Lyra Direct HSV 1+2/VZV Assay

The Lyra Direct HSV 1+2/VZV Assay is a multiplex in vitro test that detects and differentiates Herpes simplex virus 1, Herpes simplex virus 2, and Varicella-zoster virus nucleic acids isolated and purified from cutaneous or mucocutaneous swab specimens obtained from symptomatic patients.

A multiplex real-time PCR reaction is carried out under optimized conditions in a single tube generating amplicons for HSV-1, HSV-2, VZV, and the Process Control (PRC). Identification of HSV-1, HSV-2, VZV, and the PRC occurs by the use of target-specific primers and fluorescent-labeled probes that hybridize to conserved regions in the genomes of HSV-1, HSV-2, VZV and the PRC.

The Lyra Direct HSV 1+2/VZV Assay has one-step reagent set-up and a three-step sample prep. Test results are available in less than 70 minutes. The Lyra Direct HSV 1+2/VZV Assay is available for use on Applied Biosystems® 7500 Fast Dx, Biorad CFX 96, QuantStudio™ Dx Real-Time PCR Instrument, and Cepheid® SmartCycler® II.

The Lyra Direct HSV 1+2/VZV Assay is one in a growing menu of PCR tests and is used as an aid in the differential diagnosis of Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) and Varicella-zoster virus (VZV) also known as Human herpes virus 3. VZV is the causative agent for chicken pox and shingles.

ตรวจหาและจำแนก  DNA ของเชื้อ Herpes Simplex Virus 1 (HSV-1), Herpes Simplex Virus 2 (HSV-2) และ Varicella-Zoster Virus 
Multiplex Real-Time PCR
สวอปจากบริเวณที่มีแผล Cutaneous หรือ Mucocutaneous

Cutaneous Lesions HSV-1: 100%, HSV-2: 97.1%, VZV: 96.3%
Mucocutaneous Lesions HSV-1: 95.1%, HSV-2: 97.9%, VZV: 100%

Cutaneous Lesions HSV-1: 98.8%, HSV-2: 96.7%, VZV: 96.4%
Mucocutaneous Lesions HSV-1: 98.2%, HSV-2: 97.1%, VZV: 99.3%

Quidel Corporation, USA

Back to Top